BioMed Research International / 2019 / Article / Tab 2

Clinical Study

A Nomogram Predicting Microvascular Invasion Risk in BCLC 0/A Hepatocellular Carcinoma after Curative Resection

Table 2

Univariate analysis of factors affecting MVI positivity in the training group.

VariableMVI Negative MVI Positive T/P value
(n=32)(n=28)

Age, y53.9±12.949.1±12.11.4890.142
Gender (male, female)28/422/60.3350.563
BMI, Kg/m222.7±3.922.8±3.5-0.0560.955
PLT,/L165.1±99.9231.1±174.9-1.8250.073
ALB, g/L41.2±5.540.1±6.50.7710.444
TB, umol/L20.2±29.415.5±8.00.8180.417
ALT, U/L57.4±70.463.0±85.4-0.2780.782
AST, U/L45.5±46.085.5±131.5-1.6150.112
GGT, U/L102.6±242.6113.8±119.0-0.2230.824
PT, S13.8±1.213.4±0.81.5030.138
PTA, %91.8±14.195.6±11.1-1.1560.253
Liver Function Grading (A/B)30/228/0- - -0.494
HBV DNA(<10e3, ≥ 10e3IU/mL)28/418/104.4990.034
AFP(≤400,>400ng/ml)25/720/80.3570.550
HCV (Absent, Present)31/128/0- - -1.000
Tumor size, cm4.3±2.77.9±4.1-3.940<0.001
CT value in unenhanced phase (≤42.5,>42.5)17/1511/171.1490.284
CT value in artery phase(≤66.5,>66.5)12/208/200.5360.464
CT value in venous phase(≤102,>102)27/517/114.2750.039
CT value in delayed phase(≤103.5,>103.5)31/120/85.7200.017
Located in the left lobe (Absent, Present)24/820/80.0970.755
Capsule (Absent, Present)24/820/80.0970.755
With smooth margin (Absent, Present)26/625/30.2570.612
Peritumoral enhancement (Absent, Present)29/318/106.1040.013
Visible small blood vessel (Absent, Present)17/154/249.9020.002
The distance from the IVC4.0±2.42.3±1.93.0010.004
The distance from the portal vein branches4.0±1.83.0±2.31.8700.067
Liver cirrhosis (Absent, Present)17/1518/100.7650.382

P < 0.05
Abbreviations: BMI: body mass index; PLT: platelet; ALB: albumin; TB: total bilirubin; ALT: alanine aminotransferase; AST: aspartate aminotransferase; GGT: gamma-glutamyl transpeptidase; PT: prothrombin time; PTA: prothrombin activity; HBV: hepatitis B virus; AFP: alpha fetoprotein; HCV: hepatitis C virus.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.